Patient Questions and Expert Answers in Psoriasis: Clinical Pearls
Please join Mark G. Lebwohl, MD, Joel M. Gelfand, MD, MSCE, and Jeffrey M. Weinberg, MD, for a panel discussion of complex cases in psoriatic disease.
This activity is a collaboration between the National Psoriasis Foundation and Medscape, LLC. To view the activity, please click on the link below. You will be prompted to login to Medscape prior to viewing the activity.
This activity is supported by educational grants from Abbvie, Inc., and Lilly.
The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Psoriasis Foundation designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Dermatologists, Rheumatologists, Allied Health, Primary Care
Upon completion of this activity, participants will:
- Demonstrate greater confidence in the ability to identify and consider key factors in creating comprehensive management plans for patients with psoriasis
- Have greater competence related to treating patients with moderate-to-severe psoriasis based on severity and patient characteristics
- Have increased knowledge regarding the appropriate strategies for counseling patients with psoriasis and comorbid conditions such as psoriatic arthritis
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Janssen Research & Development, LLC; Kadmon Corporation, LLC; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Vidac
Served as an advisor or consultant for: Coherus Biosciences; Dermira Inc.; Dr. Reddy's Laboratories Ltd.; Janssen Pharmaceuticals, Inc.; Menlo Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Lilly
Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi
Other: Co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma
Associate Clinical Professor, Dermatology at Mount Sinai St. Luke's, West, and Beth Israel Medical Center, New York, New York
Dr. Weinberg has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; LEO Pharma Inc.; Lilly; Valeant Pharmaceuticals International
Received grants for clinical research from: AbbVie Inc.; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation